Precision Medicine in Oncology®

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Latest News

non–small cell lung cancer |  Image Credit: © yodiyim - stock.adobe.com
Adagrasib Improves PFS, ORR in Previously Treated KRAS G12C–Mutant NSCLC

March 28th 2024

Adagrasib improved progression-free survival and objective response rates vs docetaxel in pretreated KRAS G12C–mutant non–small cell lung cancer.

Carlos Rojas, Centro de Investigacion Clinica, Bradford Hill
MK-1084 Alone and Plus Pembrolizumab Shows Early Safety, Activity in KRAS G12C+ Solid Tumors

March 27th 2024

Masakazu Toi, MD, PhD
Capivasertib/Fulvestrant Wins Approval in Japan for Advanced HR+/HER2– Breast Cancer With PIK3CA, AKT1, or PTEN Alterations

March 27th 2024

FDA
FDA Grants Priority Review to Revumenib for R/R KMT2A+ AML/ALL

March 26th 2024

FDA
FDA Accepts NDA for Ensartinib in Metastatic ALK+ NSCLC

March 13th 2024

Video Series
Video Interviews
Podcasts

More News